EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Overcoming therapeutic inertia in newly diagnosed type 2 diabetes: Protocol of a randomized, quality improvement trial

Thanh K Thai, Christine A Board, Joshua R Nugent, Jessica L Johnston, Esther Y Huynh, Cindy Hanh Chen, Andy H Chan, Richard W Grant, Lisa K Gilliam, Anjali Gopalan

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2024.107751 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Thanh K Thai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente San Francisco Medical Center, San Francisco, CA, United States of America. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Metformin. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic inertia, the delay in the appropriate initiation and intensification of recommended therapies, is a major contributor to the lack of improvement in type 2 diabetes outcomes over the past decade. Therapeutic inertia during the period following diagnosis, when improvements in glycemic control can have lasting benefits, is often overlooked. Technology and team-based care approaches can effectively address therapeutic inertia. Here, we describe the protocol for a randomized, quality improvement trial targeting metformin-related therapeutic inertia among adults with recently diagnosed type 2 diabetes and a hemoglobin A1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinHypoglycemic AgentsMetforminQuality ImprovementHumansDelivery of Health Care, IntegratedGlycemic ControlPharmacistsPractice Patterns, Physicians'Primary Health CareRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Clinical inertiaDiabetesQuality improvementTrial

Substanzen

Glycated HemoglobinHypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Kaiser Permanente San Francisco Medical Center, San Francisco, CA, United States of America.
  • Kaiser Permanente Northern California Division of Research, Pleasanton, CA, United States of America.
  • Kaiser Permanente Daly City Medical Offices, Daly City, CA, United States of America.
  • Kaiser Permanente Redwood City Medical Center, Redwood City, CA, United States of America.
  • Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA, United States of America.
  • Kaiser Permanente Northern California Division of Research, Pleasanton, CA, United States of America. Electronic address: Anjali.Gopalan@kp.org.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Thai, T. K., Board, C. A., Nugent, J. R., Johnston, J. L., Huynh, E. Y., Chen, C. H., Chan, A. H., Grant, R. W., Gilliam, L. K., & Gopalan, A. (2025). Overcoming therapeutic inertia in newly diagnosed type 2 diabetes: Protocol of a randomized, quality improvement trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107751

Vancouver

Thai TK, Board CA, Nugent JR, Johnston JL, Huynh EY, Chen CH, et al. Overcoming therapeutic inertia in newly diagnosed type 2 diabetes: Protocol of a randomized, quality improvement trial. Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2024.107751

BibTeX
@article{Thai2025,
  author = {Thai, Thanh K and Board, Christine A and Nugent, Joshua R and Johnston, Jessica L and Huynh, Esther Y and Chen, Cindy Hanh and Chan, Andy H and Grant, Richard W and Gilliam, Lisa K and Gopalan, Anjali},
  title = {Overcoming therapeutic inertia in newly diagnosed type 2 diabetes: Protocol of a randomized, quality improvement trial},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2024.107751}
}
Kostenlos starten →